|
LT2502911T
(lt)
|
2004-06-24 |
2017-09-11 |
Vertex Pharmaceuticals Incorporated |
Atp surišančios kasetės transporterių moduliatoriai
|
|
EP1945632B1
(en)
|
2005-11-08 |
2013-09-18 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic modulators of atp-binding cassette transporters
|
|
WO2007079139A2
(en)
|
2005-12-28 |
2007-07-12 |
Vertex Pharmaceuticals, Inc. |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
EP2021797B1
(en)
|
2006-05-12 |
2011-11-23 |
Vertex Pharmaceuticals, Inc. |
Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
EP2639224B1
(en)
|
2007-12-07 |
2016-08-24 |
Vertex Pharmaceuticals Incorporated |
Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
|
|
SI2225230T1
(sl)
|
2007-12-07 |
2017-03-31 |
Vertex Pharmaceuticals Incorporated |
Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
|
|
HRP20180328T1
(hr)
|
2008-08-13 |
2018-04-20 |
Vertex Pharmaceuticals Inc. |
FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
JP2012504143A
(ja)
|
2008-09-29 |
2012-02-16 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
|
|
EP2365972B1
(en)
|
2008-11-06 |
2014-12-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
SI2408750T1
(sl)
|
2009-03-20 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
|
|
US20110251253A1
(en)
|
2010-03-25 |
2011-10-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
|
|
ES2568802T3
(es)
|
2010-04-09 |
2016-05-04 |
Ekso Bionics |
Sistema de manipulación de carga de exoesqueleto y procedimiento de uso
|
|
ES2608474T3
(es)
|
2010-04-22 |
2017-04-11 |
Vertex Pharmaceuticals Incorporated |
Proceso de producción de compuestos indol cycloalkylcarboxamido
|
|
CA2796642A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
|
RU2013113627A
(ru)
|
2010-08-27 |
2014-10-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтическая композиция и ее введения
|
|
JP6063455B2
(ja)
|
2011-05-18 |
2017-01-18 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたイバカフトルの誘導体
|
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
|
WO2013038386A1
(en)
*
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
|
EP2819670A1
(en)
|
2012-02-27 |
2015-01-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administration thereof
|
|
WO2014014841A1
(en)
|
2012-07-16 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
LT3470063T
(lt)
|
2012-11-02 |
2025-02-10 |
Vertex Pharmaceuticals Incorporated |
Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
|
|
MY183582A
(en)
|
2012-11-19 |
2021-02-26 |
Vertex Pharmaceuticals Europe Ltd |
Deuterated cftr potentiators
|
|
ES2885181T3
(es)
|
2014-04-15 |
2021-12-13 |
Vertex Pharma |
Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
|
|
TWI735416B
(zh)
|
2014-10-06 |
2021-08-11 |
美商維泰克斯製藥公司 |
囊腫纖維化症跨膜傳導調節蛋白之調節劑
|
|
MX366556B
(es)
|
2014-10-31 |
2019-07-12 |
Abbvie Sarl |
Cromanos sustituidos y metodo de uso.
|
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
UA124619C2
(uk)
|
2015-09-21 |
2021-10-20 |
Вертекс Фармасьютікалз (Юроп) Лімітед |
Введення дейтерованих підсилювачів cftr
|
|
CA3000483C
(en)
|
2015-10-06 |
2024-02-13 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for modulating cftr
|
|
RU2724345C2
(ru)
|
2015-10-09 |
2020-06-23 |
Галапагос Нв |
N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
|
|
SI3519401T1
(sl)
*
|
2016-09-30 |
2022-01-31 |
Vertex Pharmaceuticals Incorporated |
Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
WO2018080591A1
(en)
|
2016-10-27 |
2018-05-03 |
Vertex Pharmaceuticals (Europe) Limited |
Methods of treatment with deuterated cftr potentiators
|
|
CN110267948B
(zh)
|
2016-12-09 |
2023-12-08 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
|
|
MA49631A
(fr)
*
|
2017-07-17 |
2020-05-27 |
Vertex Pharma |
Méthodes de traitement de la fibrose kystique
|
|
US10654829B2
(en)
|
2017-10-19 |
2020-05-19 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of CFTR modulators
|
|
CA3082444A1
(en)
|
2017-12-01 |
2019-06-06 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
KR102716244B1
(ko)
|
2017-12-08 |
2024-10-14 |
버텍스 파마슈티칼스 인코포레이티드 |
낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
|
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
|
AU2019222758B2
(en)
|
2018-02-15 |
2022-07-07 |
Vertex Pharmaceuticals Incorporated |
Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
|
|
PT3880197T
(pt)
|
2018-11-14 |
2023-05-09 |
Vertex Pharma |
Métodos de tratamento para a fibrose quística
|
|
TWI848092B
(zh)
|
2019-04-03 |
2024-07-11 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白調節劑
|
|
TWI899097B
(zh)
|
2019-08-14 |
2025-10-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
EP4225447A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US20230374038A1
(en)
|
2020-10-07 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US20230373935A1
(en)
|
2020-10-07 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP4225765A2
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2022076626A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2022076629A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
MX2023004074A
(es)
|
2020-10-07 |
2023-07-05 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
|
|
EP4225762A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2022076628A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP4225446A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
KR20230123522A
(ko)
*
|
2020-11-18 |
2023-08-23 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막관통 전도도 조절제로서 사용하기 위한 1,3,4-옥사디아졸 고리를 함유하는 거대환
|